Evidence map›Paper›PMID 40214824›Full record

ArticleClinical oral investigations2025

Radioactivity levels in the saliva of patients undergoing targeted radioligand therapy with [

Christian Schedeit, Nasir Gözlügöl, Radi Saiyed Alsheikh, Mohamed Shelan, Robert Seifert, Federico Caobelli, Urs Borner, Tateyuki Iizuka, Benoît Schaller, Axel Rominger and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christian SchedeitDepartment of Cranio-Maxillofacial Surgery, Bern University Hospital, Inselspital, University of Bern, Bern, CH-3010, Switzerland.
Nasir GözlügölDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.
Radi Saiyed AlsheikhDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.
Mohamed ShelanDepartment of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Robert SeifertDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.
Federico CaobelliDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.
Urs BornerDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
Tateyuki IizukaDepartment of Cranio-Maxillofacial Surgery, Bern University Hospital, Inselspital, University of Bern, Bern, CH-3010, Switzerland.
Benoît SchallerDepartment of Cranio-Maxillofacial Surgery, Bern University Hospital, Inselspital, University of Bern, Bern, CH-3010, Switzerland.
Axel RomingerDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.
Paul CummingDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.
Ali Afshar-OromiehDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland. ali.afshar@insel.ch.
Konstantinos G ZeimpekisDepartment of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Freiburgstr. 18, Bern, CH- 3010, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe number of patients receiving radioligand therapy (RLT) has risen sharply in recent years. This raises concerns about possible risks to dental healthcare workers due to their exposure to the patients and their saliva. We therefore set about to measure the salivary radioactivity in patients undergoing MATERIALS AND

methodsWe recruited in-house RLT patients receiving [

resultsBoth cohorts exhibited increases in salivary radioactivity, attaining peaks at 2 h p.i. of [

conclusionSalivary radioactivity peaks earlier and at lower levels in [ CLINICAL RELEVANCE: Salivary radioactivity of patients undergoing

Indexed as

Heterocyclic Compounds, 1-RingLutetiumOrganometallic CompoundsRadiopharmaceuticalsSalivaAdultAgedFemaleHalf-LifeHumansMaleMiddle AgedHeterocyclic Compounds, 1-RingLutetiumOrganometallic CompoundsRadiopharmaceuticals177Lu-PSMAMRONJProstate cancerPSMARadionuclide therapySaliva

Identifiers

PMID40214824
PMCPMC11991938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.